Bimekizumab
Bimekizumab (INN) is a humanized anti-IL17A and IL-17F monoclonal antibody that is being investigated for ankylosing spondylitis, psoriatic arthritis, and psoriasis. This drug is being developed by Belgian pharmaceutical UCB. As of 2018, bimekizumab is undergoing Phase III trials.
Link from a Wikipage to another Wikipage
primaryTopic
Bimekizumab
Bimekizumab (INN) is a humanized anti-IL17A and IL-17F monoclonal antibody that is being investigated for ankylosing spondylitis, psoriatic arthritis, and psoriasis. This drug is being developed by Belgian pharmaceutical UCB. As of 2018, bimekizumab is undergoing Phase III trials.
has abstract
Bimekizumab (INN) is a humaniz ...... s undergoing Phase III trials.
@en
CAS number
1418205-77-2
FDA UNII code
09495UIM6V
KEGG
Wikipage page ID
58,571,254
page length (characters) of wiki page
Wikipage revision ID
1,001,780,981
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
KEGG
D11550
@en
mab type
mab
@en
source
zu
@en
target
type
mab
@en
wikiPageUsesTemplate
subject
comment
Bimekizumab (INN) is a humaniz ...... s undergoing Phase III trials.
@en
label
Bimekizumab
@en